Skip to content
MondayNightIBD ~ Treat-to-Target Clinical Convo
October 21, 2024 ~ Jami Kinnucan, MD
**Pre-assessment**
Before you view this activity, please take this pre-assessment.
Taking this pre-assessment does not immediately qualify learners to earn credit.
Certificates of credit will only be sent to learners who also receive a passing score on the post-test (separate from this survey), and fill out the evaluation form and application for credit.
*
1.
What are your specialty and credentials?
(Required.)
IBD Specialist
General GI
Colorectal Surgeon
Fellow/Trainee
APP
Nurse
PharmD
Other (please specify)
2.
What is your community of practice?
Academic
Community
Industry
*
3.
In the CALM study comparing conventional treatment vs T2T treatment escalation in bionaive Crohn's patients starting adalimumab, mucosal healing at week 48 was defined as?
(CDEIS: Crohn's Disease Endoscopic Index of Severity)
(Required.)
CDEIS 0 and no ulcers
CDEIS = 0 (normal exam)
CDEIS <4 and no deep ulcers
Deep ulcers< 10% of bowel surface
*
4.
55 with recent diagnosis of colonic Crohn’s disease, SESCD 6, FCP 850, started on Vedolizumab. At 3 month FCP 100, Colonoscopy at 1yr : endo remission.
According to the AGA 2023 guidelines, how can you periodically (every few months) rule out active inflammation moving forward?
(Required.)
Clincial symtoms check
FCP check <150
Endoscopy
CT or MRI
5.
Completing this pre-survey does not qualify you for a CME certificate. Only after completing the post-survey & evaluation form will a certificate be issued.
First & Last Name, Credentials
🔗
Proceed to activity on X/MondayNightIBD
🔗
Proceed to post-survey
(post-survey completion must occur on or after activity launch date to be valid for claiming credit)
